Results 11 to 20 of about 255,577 (258)

Fibroblast Growth Factor 23 and Sarcopenia in Maintenance Haemodialysis Population [PDF]

Journal of Cachexia, Sarcopenia and Muscle
Background Sarcopenia is defined as the loss of muscle mass, strength, and/or performance. It is strongly associated with all‐cause mortality. Fibroblast growth factor 23 (FGF23) is markedly elevated in patients with chronic kidney disease, especially ...
Limy Wong, Rachel Kenny, Jenny Y. Y. Ooi, Yung Shing Tsang, Emily Schembri, Lawrence P. McMahon   +5 more
doaj   +2 more sources

Fibroblast growth factor 23 as a risk factor for incident diabetes [PDF]

Current Opinion in Nephrology & Hypertension
Purpose of review Diabetes is a major global health concern, affecting millions and increasing morbidity and mortality. Recent research highlights fibroblast growth factor 23 (FGF23) as a potential contributor to type 2 diabetes and its cardiovascular complications.
de Borst MH.
openaire   +3 more sources

Effects of Single Vitamin D Injection (200,000 Units) on Serum Fibroblast Growth Factor 23 and Sclerostin Levels in Subjects with Vitamin D Deficiency [PDF]

Endocrinology and Metabolism, 2017
BackgroundVitamin D deficiency remains common in all age groups and affects skeletal and non-skeletal health. Fibroblast growth factor 23 is a bone-derived hormone that regulates phosphate and 1,25-dihydroxyvitamin D homeostasis as a counter regulatory ...
Dongdong Zhang, Da Hea Seo, Han Seok Choi, Hye-Sun Park, Yoon-Sok Chung, Sung-Kil Lim   +5 more
doaj   +1 more source

Multiple faces of fibroblast growth factor-23 [PDF]

Current Opinion in Nephrology and Hypertension, 2016
This review examines the role of fibroblast growth factor-23 (FGF-23) in mineral metabolism, innate immunity and adverse cardiovascular outcomes.FGF-23, produced by osteocytes in bone, activates FGFR/α-Klotho (α-Kl) complexes in the kidney. The resulting bone-kidney axis coordinates renal phosphate reabsorption with bone mineralization, and creates a ...
Xiaobin, Han, L Darryl, Quarles
openaire   +2 more sources

Evocalcet with vitamin D receptor activator treatment for secondary hyperparathyroidism

PLoS ONE, 2022
This ad hoc analysis of a previously conducted phase 3 head-to-head comparison study of evocalcet and cinacalcet in secondary hyperparathyroidism patients undergoing maintenance hemodialysis evaluated the efficacy and safety of combined once-daily oral ...
Takashi Shigematsu, Shinji Asada, Yuichi Endo, Takehisa Kawata, Masafumi Fukagawa, Tadao Akizawa   +5 more
doaj   +2 more sources

Fibroblast Growth Factor 23 and Inflammation in CKD [PDF]

Clinical Journal of the American Society of Nephrology, 2012
Summary Background and objectives Levels of fibroblast growth factor 23 (FGF23) and inflammatory markers are commonly elevated in CKD, and each is associated with adverse clinical outcomes. This study tested the hypothesis that FGF23 is independently associated with inflammation in CKD.
Jair, Munoz Mendoza, Tamara, Isakova, Ana C, Ricardo, Huiliang, Xie, Sankar D, Navaneethan, Amanda H, Anderson, Lydia A, Bazzano, Dawei, Xie, Matthias, Kretzler, Lisa, Nessel, L Lee, Hamm, Lavinia, Negrea, Mary B, Leonard, Dominic, Raj, Myles, Wolf   +14 more
openaire   +2 more sources

Neurofibromatosis type 1 associated with hypophosphatemic osteomalacia due to hypersecretion of fibroblast growth factor 23: a case report

Journal of Medical Case Reports, 2020
Background Neurofibromatosis type 1 is characterized by multiple café au lait spots and cutaneous and plexiform neurofibromas, and is one of the most common autosomal dominant hereditary disorders caused by mutations of the neurofibromatosis type 1 tumor
Takahiko Obo, Nobuyuki Koriyama, Akinori Tokito, Kazuma Ogiso, Yoshihiko Nishio   +4 more
doaj   +1 more source

Fibroblast Growth Factor-23 (FGF-23) e Sindrome Cardiorenale

Giornale di Clinica Nefrologia e Dialisi, 2015
non disponibile (Cardionephrology)
Luca Di Lullo, Rodolfo Rivera, Antonio De Pascalis, Fulvio Floccari, Vincenzo Barbera, Claudio Ronco, Alberto Santoboni1   +6 more
doaj   +1 more source

Serum intact fibroblast growth factor 23 in healthy paediatric population

Open Medicine, 2021
It is believed that fibroblast growth factor 23 (FGF23) can become an early biomarker of chronic kidney disease progression. Data on FGF23 age dependency are inconsistent.
Stanczyk Malgorzata, Chrul Slawomir, Wyka Krystyna, Tkaczyk Marcin   +3 more
doaj   +1 more source

MicroRNA-297a regulates vascular calcification by targeting fibroblast growth factor 23 [PDF]

Iranian Journal of Basic Medical Sciences, 2016
Objective(s): Vascular calcification is one the major characteristics in patients with various types of chronic inflammatory disorders. MiRNAs have been shown to be involved in many normal biological functions as well as diseases; however, their role in ...
Shouhua Zheng, Shuijun Zhang, Yan Song, Wenzhi Guo, Wenlong Zhai, Xinguang Qiu, Jianhua Li   +6 more
doaj   +1 more source